In patients undergoing percutaneous cardiovascular procedures, RenalGuard was associated with a reduced risk of CA-AKI and acute pulmonary edema compared with standard periprocedural hydration strategies.Īcute kidney injury Angiografía coronaria Angioplastia Contrast media Coronary angiography Lesión renal aguda Medios de contraste yodado Nefropatía inducida por contraste Percutaneous coronary intervention.Ĭopyright © 2023. These results were consistent in multiple sensitivity analyses. Se postula que este mecanismo, disparado por la osmolaridad del contraste, generaría un disbalance entre las sustancias vasoconstrictoras (vasopresina, endotelina, adenosina, calcio) y vasodilatadoras renales. The Bayesian analysis also showed that RenalGuard had a high probability of ranking first for all the secondary outcomes. Tras la inyección del contraste yodado, ocurre un aumento transitorio del flujo renal y luego una disminución sostenida del mismo. No significant differences were observed for the other secondary endpoints. RenalGuard was associated with a significant relative reduction in CA-AKI (median RR, 0.54 95%CrI, 0.31-0.86) and acute pulmonary edema (median RR, 0.35 95%CrI, 0.12-0.87). A Bayesian random-effect risk ratio (RR) with corresponding 95% credibility interval (95%CrI) was calculated for each outcome. Secondary outcomes were all-cause death, cardiogenic shock, acute pulmonary edema, and renal failure requiring renal replacement therapy. En la mayoría de los casos es transitoria y reversible, aunque provoca un aumento de la morbimortalidad intrahospitalaria en. La nefropatía inducida por el contraste es la reacción adversa más importante. We searched Medline, Cochrane Library and Web of Science for randomized trials of RenalGuard vs standard periprocedural hydration strategies. Los medios de contraste yodados son ampliamente utilizados en los Servicios de Radiología con muy baja tasa de efectos adversos. We used a Bayesian framework to perform a meta-analysis of RenalGuard as a CA-AKI preventive strategy. The evidence on RenalGuard in patients undergoing percutaneous cardiovascular procedures is sparse. RenalGuard, which provides real-time matching of intravenous hydration with furosemide-induced diuresis, is an alternative to standard periprocedural hydration strategies. Contrast-associated acute kidney injury (CA-AKI) is a potential complication of procedures requiring administration of iodinated contrast medium.
0 Comments
Leave a Reply. |